About

Publications While At HealthPartners

selected publications

Journal Article

18 Years - VISION and IVY Networks, September 2023-January 2024. 

MMWR: Morbidity and Mortality Weekly Report. 2024

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 

Journal of Infectious Diseases. 2024

Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States. 

MMWR: Morbidity and Mortality Weekly Report. 2024

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 

Lancet (London, England). 2024

Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 

Influenza and other respiratory viruses. 2024

Vaccine effectiveness against SARS-CoV-2 related hospitalizations in people who had experienced homelessness or incarceration - findings from the Minnesota EHR Consortium. 

Journal of Community Health. 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 

American Journal of Transplantation. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. 

Vaccine. 2023

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. 

Lancet Reg Health Am. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Relationships between social vulnerability and coronavirus disease 2019 vaccination coverage and vaccine effectiveness. 

Clinical Infectious Diseases. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Contact

full name

M. W. Tenforde

Quick Info

 

Collaboration

Co-author network

Map of science